GT BIOPHARMA
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immunology therapeutic products based on our proprietary Trispecific Killer Engagers (TriKE™) target-directed Natural Killer (NK) cell engager platform. The TriKE™ NK protein biologic platform is designed to harness and amplify the body’s native immune system for hope for patients with cancer and infectious diseases.
GT BIOPHARMA
Industry:
Biotechnology Health Care Medical
Founded:
1965-01-01
Address:
Westlake Village, California, United States
Country:
United States
Website Url:
http://www.gtbiopharma.com
Total Employee:
1+
Status:
Active
Contact:
310-860-5184
Total Funding:
88.33 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Apache Microsoft Exchange Online Amazon
Similar Organizations
Illumina
Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2005-09-21 | BioCheck | BioCheck acquired by GT Biopharma | 6 M USD |
| 1998-01-06 | Innovative Medical Systems | Innovative Medical Systems acquired by GT Biopharma | N/A |
Investors List
Armando Soto
Armando Soto investment in Post-IPO Equity - GT Biopharma
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-18 | GT Biopharma Appoints Manu Ohri as Chief Financial Officer |
Official Site Inspections
http://www.gtbiopharma.com
- Host name: ec2-174-129-30-187.compute-1.amazonaws.com
- IP address: 174.129.30.187
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "GT Biopharma"
Management Team :: GT Biopharma, Inc. (GTBP)
Michael Breen. Executive Chairman, Board of Directors, Interim Chief Executive Officer. Michael Breen is an English qualified solicitor/attorney and was formerly the Managing Director of the …See details»
Profile :: GT Biopharma, Inc. (GTBP)
GT Biopharma, Inc. (NASDAQ: GTBP) is a clinical stage immuno-oncology company focused on developing innovative therapies based on the Company's proprietary NK cell engager (TriKE …See details»
GT Biopharma Announces Executive Leadership Transition to …
For more information, please visit gtbiopharma.com. Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and …See details»
GT Biopharma - Crunchbase Company Profile & Funding
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immunology therapeutic products based on our proprietary Trispecific Killer Engagers (TriKE™) target-directed Natural …See details»
GT Biopharma Announces Executive Leadership Transition to …
Nov 8, 2021 [email protected] 414-351-9758 . LifeSci Advisors Corey Davis, Ph.D. [email protected] 212-915-2577 . View original content ...See details»
GT Biopharma, Inc. | LinkedIn
GT Biopharma, Inc. | 884 followers on LinkedIn. Focused on the next generation of immunotherapies by leveraging our proprietary TriKE platform technology. (NASDAQ:GTBP) | Using our proprietary ...See details»
GT Biopharma, Inc. Company Profile - Dun & Bradstreet
Company Description: GT Biopharma (formerly OXIS International) is an immuno-oncology biotech working with its proprietary platforms to develop innovative treatments for such …See details»
GT Biopharma, Inc. (GTBP) Company Profile
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell …See details»
GT BioPharma Reports Third Quarter 2021 Financial Results and …
For more information, please visit gtbiopharma.com. Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties and …See details»
GT Biopharma - Overview, News & Similar companies - ZoomInfo
Jun 9, 2024 GT Biopharma contact info: Phone number: (415) 919-4040 Website: www.gtbiopharma.com What does GT Biopharma do? GT Biopharma, Inc. is a clinical stage …See details»
GT Biopharma, Inc. (GTBP) - Yahoo Finance
Find the latest GT Biopharma, Inc. (GTBP) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Investor Relations :: GT Biopharma, Inc. (GTBP)
Sign up for email alerts. Be the first to receive breaking news. Sign up todaySee details»
GT Biopharma Reports First Quarter 2024 Financial Results and …
For more information, please visit gtbiopharma.com. Forward-Looking Statements. Certain statements in this press release may constitute "forward-looking statements" regarding future …See details»
GT Biopharma, Inc. (GTBP) Stock Price, News, Quote & History
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer …See details»
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial ...
For more information, please visit gtbiopharma.com. Forward-Looking Statements. Certain statements in this press release may constitute "forward-looking statements" regarding future …See details»
GT Biopharma Reports Fourth Quarter and Year End 2020 Results …
Apr 19, 2021 For more information, please visit gtbiopharma.com. Forward-Looking Statements This press release contains certain forward-looking statements that involve risks, uncertainties …See details»
GT Biopharma, Inc. (GTBP) Stock Price, Quote & News - Stock …
5 days ago GT Biopharma Reports Third Quarter 2024 Financial Results. SAN FRANCISCO, CALIFORNIA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) …See details»
GT Biopharma Reports Third Quarter Fiscal 2022 Financial Results …
For more information, please visit gtbiopharma.com. Forward-Looking Statements Certain statements in this press release may constitute "forward-looking statements" regarding future …See details»
GT Biopharma Reports First Quarter 2023 Financial Results and …
Cash of approximately $19.9 million as of March 31, 2023, provides ample runway to fund operations into Q2 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 …See details»